Todd Brady, Aldeyra Therapeutics CEO
Aldeyra eyes potentially pivotal trial in retinitis pigmentosa after small open-label readout
A week after Aldeyra’s drug candidate was rejected by the FDA for a rare eye cancer, the biotech touted data on the asset in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
